Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Obe-cel, a potentially transformational treatment for relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia , on track for a Biologics License Application submission to the US Food & Drug...